+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Artemisinin Combination Therapy Market - Global Forecast 2026-2032- Product Image
Artemisinin Combination Therapy Market - Global Forecast 2026-2032- Product Image
Sale

Artemisinin Combination Therapy Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6013910
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Artemisinin Combination Therapy Market is projected to reach USD 414.27 Million in 2026. It is expected to continue growing at a CAGR of 6.69%, reaching USD 608.26 Million by 2032.

Artemisinin Combination Therapy: Executive Summary

Artemisinin combination therapy (ACT) is a cornerstone of treatment for uncomplicated Plasmodium falciparum malaria and is used in national malaria-control programs across endemic settings. Its role is shaped by parasite resistance, medicine quality, patient access, diagnostic capacity, procurement systems, and adherence to treatment protocols. The market is therefore best understood as part of a broader public-health and pharmaceutical-supply ecosystem rather than as a standalone product category.

Resistance, Quality, and Access Are Reshaping ACT Delivery

The landscape is being transformed by the spread and monitoring of artemisinin partial resistance, particularly in parts of the Greater Mekong Subregion and Africa. This has increased the importance of therapeutic-efficacy studies, molecular surveillance, pharmacovigilance, and timely updates to treatment guidelines. At the same time, substandard or falsified antimalarial products, stock interruptions, delayed diagnosis, and uneven health-system reach continue to affect outcomes. Durable progress depends on quality-assured medicines, reliable procurement, community-level access, and integrated malaria surveillance.

Artificial Intelligence Strengthens Surveillance, Diagnosis, and Supply Planning

Artificial intelligence can support ACT programs by identifying resistance signals in genomic and therapeutic-efficacy data, improving interpretation of malaria microscopy and rapid diagnostic tests, and helping programs anticipate stock needs. Machine-learning tools may also assist geospatial targeting, outbreak detection, and adherence-support workflows. However, these applications require representative training data, external validation, human clinical oversight, strong data governance, and safeguards against excluding rural or underdiagnosed populations. AI should augment-not replace-national malaria programs, laboratory networks, and clinical judgment.

Regional Insights: Diverse Epidemiology Requires Locally Adapted ACT Strategies

North America and Europe primarily contribute through research, regulation, financing, travel-medicine services, and support for elimination programs rather than through broad endemic demand. Latin America faces heterogeneous transmission patterns and requires strategies aligned with local species distribution, resistance surveillance, and remote-access challenges. The Middle East combines lower-transmission settings with population movement and imported infections, making diagnosis and cross-border coordination important. Africa carries the largest burden of malaria and therefore places exceptional emphasis on quality-assured pediatric formulations, community delivery, diagnostic coverage, and resistance monitoring. Asia-Pacific includes both high-burden settings and areas pursuing elimination, with the Greater Mekong Subregion requiring especially close attention to artemisinin and partner-drug resistance.

Group Insights: Policy Blocs Influence Procurement and Technical Coordination

ASEAN cooperation is relevant to cross-border surveillance, elimination initiatives, and coordinated responses to resistance in Southeast Asia. BRICS members include major malaria-affected countries and can contribute to manufacturing capacity, research collaboration, diagnostics, and health-system strengthening. The European Union and G7 are important for regulatory alignment, development financing, research support, and supply-chain resilience. GCC countries generally engage through health-system preparedness, imported-case management, and regional coordination. NATO members may encounter malaria mainly through military deployment and travel-health contexts, while their broader capabilities can support research, logistics, and outbreak-response partnerships. These groupings are complementary but do not replace country-led malaria programs.

Country Insights: National Context Determines ACT Priorities

Australia focuses on imported malaria, regional partnerships, surveillance, and support for Pacific and Asia-focused research. Brazil combines substantial Amazon-region needs with national surveillance, diagnosis, and elimination priorities. Canada and the United States emphasize travel-related disease management, research, financing, and technical assistance. China is advancing malaria elimination and maintaining vigilance over imported cases and regional resistance. France, Germany, Italy, Spain, and the United Kingdom contribute through public-health agencies, research institutions, procurement support, and imported-case care, with France also addressing overseas territories and endemic partnerships. India requires broad access across diverse transmission settings and continued attention to quality, adherence, and resistance surveillance. Japan and South Korea contribute through research, development cooperation, and regional health security. Mexico manages localized transmission, border and travel-related risks, and elimination-oriented surveillance. Russia addresses imported malaria, diagnostics, and public-health preparedness in relation to travel and neighboring regions.

Action Priorities for Leaders: Protect Efficacy and Reach the Right Patients

Industry and public-health leaders should prioritize quality-assured ACT supply, pediatric and dispersible formulations, transparent procurement, and resilient distribution to hard-to-reach communities. They should align product strategies with national guidelines, invest in resistance and therapeutic-efficacy surveillance, and support diagnostic confirmation before treatment where feasible. Partnerships with ministries, laboratories, community-health workers, and financing institutions can improve adherence and pharmacovigilance. Leaders should also establish responsible AI governance, validate digital tools in real-world settings, and maintain contingency plans for supply disruptions, changing treatment guidance, and regional resistance patterns.

Research Methodology: Evidence-Based Review of ACT Ecosystem Drivers

This executive summary uses a qualitative synthesis framework focused on verified public-health and pharmaceutical evidence relevant to ACT. The assessment considers malaria epidemiology, treatment guidance, resistance surveillance, medicine quality, diagnostics, procurement, access, health-system capacity, regional coordination, and emerging digital technologies. Geographic and group comparisons are framed around documented policy and program characteristics rather than commercial estimates. Interpretation should be updated as national guidelines, resistance findings, regulatory decisions, and epidemiological conditions change.

Conclusion: ACT Effectiveness Depends on Integrated Health-System Stewardship

ACT remains central to malaria treatment, but its long-term effectiveness depends on more than medicine availability. Resistance surveillance, diagnostic accuracy, product quality, adherence, equitable access, and responsive treatment policies must operate together. Regional and international cooperation can strengthen these foundations, while carefully governed AI can improve detection and planning. Leaders who connect pharmaceutical stewardship with local health-system realities will be better positioned to preserve ACT efficacy and support malaria-control and elimination objectives.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Artemisinin Combination Therapy Market, by Active Ingredient
7.1. Introduction
7.2. Artemether Lumefantrine
7.3. Artesunate Amodiaquine
7.4. Artesunate Sulfadoxine Pyrimethamine
7.5. Dihydroartemisinin Piperaquine
8. Artemisinin Combination Therapy Market, by Dosage Form
8.1. Introduction
8.2. Injectable
8.2.1. Intramuscular
8.2.2. Intravenous
8.3. Oral Suspension
8.3.1. Granule Sachet
8.3.2. Syrup
8.4. Tablet
8.4.1. Co Packaged
8.4.2. Fixed Dose Combination
9. Artemisinin Combination Therapy Market, by Patient Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Artemisinin Combination Therapy Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Private
10.2.2. Public
10.3. Homecare
10.3.1. Caregiver Assisted
10.3.2. Self Administration
10.4. Hospitals
10.4.1. Private
10.4.2. Public
11. Artemisinin Combination Therapy Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Artemisinin Combination Therapy Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Artemisinin Combination Therapy Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Artemisinin Combination Therapy Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Ajanta Pharma Ltd
16.2. Bliss GVS
16.3. Cipla Limited
16.4. Guilin Pharmaceutical Co., Ltd.
16.5. Ipca Laboratories Ltd.
16.6. Kunming Pharmaceutical Corp.
16.7. Mylan NV
16.8. Novartis AG
16.9. Qilu Pharmaceutical Co., Ltd.
16.10. Sanofi SA
16.11. Shin Poong Pharmaceutical Co., Ltd.
16.12. Sun Pharmaceutical Industries Ltd.
16.13. Viatris, Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Artemisinin Combination Therapy Market, Years Considered for the Study
FIGURE 2. Global Artemisinin Combination Therapy Market, Research Design
FIGURE 3. Global Artemisinin Combination Therapy Market, Research Framework
FIGURE 4. Global Artemisinin Combination Therapy Market, Data Triangulation
FIGURE 5. Global Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Artemisinin Combination Therapy Market Size, by Active Ingredient, 2025 vs 2032 (%)
FIGURE 7. Global Artemisinin Combination Therapy Market Size, by Active Ingredient, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Artemisinin Combination Therapy Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 9. Global Artemisinin Combination Therapy Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Artemisinin Combination Therapy Market Size, by Patient Group, 2025 vs 2032 (%)
FIGURE 11. Global Artemisinin Combination Therapy Market Size, by Patient Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Artemisinin Combination Therapy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Artemisinin Combination Therapy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Artemisinin Combination Therapy Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Artemisinin Combination Therapy Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Artemisinin Combination Therapy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Artemisinin Combination Therapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Artemisinin Combination Therapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Artemisinin Combination Therapy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Artemisinin Combination Therapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Artemisinin Combination Therapy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Artemisinin Combination Therapy Market Segmentation & Coverage
TABLE 2. Global Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 3. Global Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 4. Global Artemether Lumefantrine Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Artemether Lumefantrine Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Artemether Lumefantrine Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Artesunate Amodiaquine Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Artesunate Amodiaquine Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Artesunate Amodiaquine Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Artesunate Sulfadoxine Pyrimethamine Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Artesunate Sulfadoxine Pyrimethamine Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Artesunate Sulfadoxine Pyrimethamine Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Dihydroartemisinin Piperaquine Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Dihydroartemisinin Piperaquine Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Dihydroartemisinin Piperaquine Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 17. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Oral Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Oral Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Oral Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Granule Sachet Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Granule Sachet Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Granule Sachet Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Syrup Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Syrup Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Syrup Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Co Packaged Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Co Packaged Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Co Packaged Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Fixed Dose Combination Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Fixed Dose Combination Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Fixed Dose Combination Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 45. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Private Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Private Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Private Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Public Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Public Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Public Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Homecare Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Homecare Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Homecare Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Caregiver Assisted Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Caregiver Assisted Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Caregiver Assisted Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Self Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Self Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Self Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Private Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Private Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Private Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Public Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Public Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Public Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Artemisinin Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Artemisinin Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. North America Artemisinin Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. North America Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 107. North America Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 108. North America Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 109. North America Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 110. North America Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 111. North America Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 112. North America Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. North America Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 114. North America Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 115. North America Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 116. North America Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Latin America Artemisinin Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Latin America Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 119. Latin America Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 120. Latin America Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 121. Latin America Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 122. Latin America Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 123. Latin America Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 124. Latin America Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Latin America Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 126. Latin America Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 127. Latin America Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 128. Latin America Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Europe Artemisinin Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Europe Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 131. Europe Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 132. Europe Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 133. Europe Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 134. Europe Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 135. Europe Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 136. Europe Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Europe Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 138. Europe Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 139. Europe Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 140. Europe Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. Middle East Artemisinin Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Middle East Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 143. Middle East Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 144. Middle East Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 145. Middle East Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 146. Middle East Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 147. Middle East Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 148. Middle East Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. Middle East Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 150. Middle East Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 151. Middle East Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 152. Middle East Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. Africa Artemisinin Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Africa Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 155. Africa Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 156. Africa Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 157. Africa Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 158. Africa Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 159. Africa Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 160. Africa Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. Africa Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 162. Africa Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 163. Africa Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 164. Africa Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. Global Artemisinin Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. ASEAN Artemisinin Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. ASEAN Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 168. ASEAN Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 169. ASEAN Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 170. ASEAN Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 171. ASEAN Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 172. ASEAN Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 173. ASEAN Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. ASEAN Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 175. ASEAN Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 176. ASEAN Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 177. ASEAN Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. GCC Artemisinin Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. GCC Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 180. GCC Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 181. GCC Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 182. GCC Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 183. GCC Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 184. GCC Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 185. GCC Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 186. GCC Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 187. GCC Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 188. GCC Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 189. GCC Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. European Union Artemisinin Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. European Union Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 192. European Union Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 193. European Union Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 194. European Union Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 195. European Union Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 196. European Union Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 197. European Union Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. European Union Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 199. European Union Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 200. European Union Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 201. European Union Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. BRICS Artemisinin Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 203. BRICS Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 204. BRICS Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 205. BRICS Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 206. BRICS Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 207. BRICS Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 208. BRICS Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 209. BRICS Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 210. BRICS Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 211. BRICS Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 212. BRICS Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 213. BRICS Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. G7 Artemisinin Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. G7 Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 216. G7 Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 217. G7 Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 218. G7 Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 219. G7 Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 220. G7 Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 221. G7 Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. G7 Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 223. G7 Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 224. G7 Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 225. G7 Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. NATO Artemisinin Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 227. NATO Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 228. NATO Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 229. NATO Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 230. NATO Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 231. NATO Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 232. NATO Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 233. NATO Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 234. NATO Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 235. NATO Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 236. NATO Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 237. NATO Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. Global Artemisinin Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 239. United States Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 240. United States Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 241. United States Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. United States Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 243. United States Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 244. United States Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 245. United States Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 246. United States Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. United States Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 248. United States Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 249. United States Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 250. United States Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Canada Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 252. Canada Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 253. Canada Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 254. Canada Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 255. Canada Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 256. Canada Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 257. Canada Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 258. Canada Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. Canada Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 260. Canada Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 261. Canada Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 262. Canada Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Mexico Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 264. Mexico Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 265. Mexico Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 266. Mexico Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 267. Mexico Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 268. Mexico Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 269. Mexico Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 270. Mexico Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. Mexico Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 272. Mexico Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 273. Mexico Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 274. Mexico Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 275. Brazil Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 276. Brazil Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 277. Brazil Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 278. Brazil Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 279. Brazil Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 280. Brazil Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 281. Brazil Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 282. Brazil Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Brazil Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 284. Brazil Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 285. Brazil Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 286. Brazil Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 287. United Kingdom Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 288. United Kingdom Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 289. United Kingdom Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 290. United Kingdom Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 291. United Kingdom Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 292. United Kingdom Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 293. United Kingdom Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 294. United Kingdom Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 295. United Kingdom Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 296. United Kingdom Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 297. United Kingdom Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 298. United Kingdom Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Germany Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 300. Germany Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 301. Germany Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 302. Germany Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 303. Germany Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 304. Germany Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 305. Germany Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 306. Germany Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 307. Germany Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 308. Germany Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 309. Germany Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 310. Germany Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 311. France Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 312. France Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 313. France Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 314. France Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 315. France Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 316. France Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 317. France Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 318. France Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 319. France Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 320. France Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 321. France Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 322. France Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 323. Russia Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
TABLE 324. Russia Artemisinin Combination Therapy Market Size, by Active Ingredient, 2017-2032 (USD Million)
TABLE 325. Russia Artemisinin Combination Therapy Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 326. Russia Artemisinin Combination Therapy Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 327. Russia Artemisinin Combination Therapy Market Size, by Oral Suspension, 2017-2032 (USD Million)
TABLE 328. Russia Artemisinin Combination Therapy Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 329. Russia Artemisinin Combination Therapy Market Size, by Patient Group, 2017-2032 (USD Million)
TABLE 330. Russia Artemisinin Combination Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 331. Russia Artemisinin Combination Therapy Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 332. Russia Artemisinin Combination Therapy Market Size, by Homecare, 2017-2032 (USD Million)
TABLE 333. Russia Artemisinin Combination Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 334. Russia Artemisinin Combination Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. Italy Artemisinin Combination Therapy Market Size, 2017-2032 (USD Million)
T

Companies Mentioned

  • Ajanta Pharma Ltd
  • Bliss GVS
  • Cipla Limited
  • Guilin Pharmaceutical Co., Ltd.
  • Ipca Laboratories Ltd.
  • Kunming Pharmaceutical Corp.
  • Mylan NV
  • Novartis AG
  • Qilu Pharmaceutical Co., Ltd.
  • Sanofi SA
  • Shin Poong Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris, Inc.

Related Topics

Related Reports

Artemisinin Combination Therapy - Global Strategic Business Report - Product Image

Artemisinin Combination Therapy - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Artemisinin Combination Therapy Market Outlook 2026-2034: Market Share and Growth Analysis by Combination Therapy Type, Formulation, Distribution Channel, End-User - Product Image

Artemisinin Combination Therapy Market Outlook 2026-2034: Market Share and Growth Analysis by Combination Therapy Type, Formulation, Distribution Channel, End-User

  • Report
  • 160 Pages
  • Global
From
Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Combination Therapies for Melanoma Market - Global Forecast 2026-2032 - Product Image

Combination Therapies for Melanoma Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From

About the Artemisinin Market

Artemisinin is a drug used to treat a variety of infectious diseases, including malaria, schistosomiasis, and filariasis. It is derived from the plant Artemisia annua, and is used in combination with other drugs to increase its effectiveness. Artemisinin is a potent antimalarial drug, and is the most effective treatment for malaria. It is also used to treat other parasitic infections, such as schistosomiasis and filariasis. Artemisinin is available in a variety of forms, including tablets, capsules, and injections. It is also available in combination with other drugs, such as mefloquine, piperaquine, and doxycycline. The drug is generally well tolerated, with few side effects. The Artemisinin market is highly competitive, with many companies offering the drug in various forms. Some of the companies in the market include Novartis, Sanofi, GlaxoSmithKline, Cipla, and Ranbaxy. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.